Gottlieb's Pfizer Board Seat: Quick, Bold, But Not Unusual For An Ex-Commish

While nearly all former FDA commissioners have served on the board of a pharmaceutical company, a Pink Sheet analysis finds that many have also served on the board of non-profit institutions after leaving public service.  

sales manager giving advice to his couple clients
Former FDA commissioners are frequently recruited to boards of companies and non-profits following their government service.

Former US Food and Drug Administration commissioner Scott Gottlieb's recent election to Pfizer Inc.'s board of directors is just a reminder of how highly sought-after FDA heads are by a broad array of stakeholders once they leave their government post.

Gottleib's post-agency move was in keeping with the tenor of his behavior when he was commissioner: swift and high-profile, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership

US FDA’s Drugs Center Lost Hundreds Of Staff Through June With 600 RIFs Coming

 

The official separation of those impacted by the reduction-in-force and some others who are leaving the agency are not yet reflected in CDER employee gains and losses data.

Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII

 

Development of the user fee commitment letter largely takes place behind closed doors between industry and FDA. Outside groups see the upcoming negotiation cycle as a chance to change this and other agency information blocks by reminding Commissioner Makary of his commitment to transparency.

Senate Bill Would Boost Oversight Of US FDA User Fee Program Following Trump Reorganization

 

Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.